bosutinib — United Healthcare
chronic myeloid leukemia
Initial criteria
- Diagnosis of chronic myelogenous / myeloid leukemia
Reauthorization criteria
- Patient does not show evidence of progressive disease while on Bosulif therapy
Approval duration
12 months